Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole.
暂无分享,去创建一个
[1] W. Haefeli,et al. CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.
[2] W. Haefeli,et al. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6 , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[3] M. Ingelman-Sundberg,et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.
[4] P. Neuvonen,et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. , 2006, Clinical pharmacology and therapeutics.
[5] Leif Bertilsson,et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.
[6] J. Boeynaems,et al. Actions of tilidine and nortilidine on cloned opioid receptors. , 2005, European journal of pharmacology.
[7] N. Wood,et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.
[8] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[9] D. Trenk,et al. Sequential First‐Pass Metabolism of Nortilidine: The Active Metabolite of the Synthetic Opioid Drug Tilidine , 2002, Journal of clinical pharmacology.
[10] D. Trenk,et al. Pharmacokinetics of Tilidine in Terminal Renal Failure , 2001, Journal of clinical pharmacology.
[11] Vinod P. Shah,et al. Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.
[12] C. Alm,et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype , 1998, Clinical pharmacology and therapeutics.
[13] M. Eichelbaum,et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.
[14] R. Wörz,et al. [Long-term treatment of chronic pain with tilidine-naloxone. An analysis of 50 patients with chronic pain conditions of non-malignant origin]. , 1995, Fortschritte der Medizin.
[15] P. Thomann,et al. Pharmacokinetics of tilidine and metabolites in man. , 1989, Arzneimittel-Forschung.
[16] R. Bayés,et al. Unreliability of the Cold Pressor Test Method in pain studies. , 1988, Methods and findings in experimental and clinical pharmacology.
[17] R. Moore,et al. Morphine and ibuprofen compared using the cold pressor test , 1988, Pain.
[18] C. Kozma,et al. A modified cold stimulation technique for the evaluation of analgesic activity in human volunteers , 1985, Pain.
[19] P. Neuvonen,et al. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl , 2007, European Journal of Clinical Pharmacology.
[20] T. Nikolaus,et al. Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons , 2004, Drugs & aging.
[21] T. Flöter,et al. [Tilidine/naloxon retard in long-term administration in chronic pain and multimorbidity. Multicenter study of long-term tolerance and effectiveness in 2 years observation]. , 2002, Fortschritte der Medizin. Originalien.
[22] H. Albeck,et al. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. , 1989, Journal of chromatography.